T Cell News and Research

Latest T Cell News and Research

Additional benefits of LAIAs over long-acting human insulin not been proven

It has so far not been proven that the long-acting insulin analogues (LAIAs) insulin detemir (trade name: Levemir) and insulin glargine (trade name: Lantus), which are approved for the treatment of type 1 diabetes, offer patients an additional benefit versus long-acting human insulin. This applies to adults as well as to children and adolescents. This is the result of the final report published by the Institute for Quality and Efficiency in Health Care (IQWiG) on 19 April 2010.

13 May 2010

Tobacco-free cigarettes may be more carcinogenic than tobacco products: Study

Using the same technique they developed to document the harmful effects of tobacco products, a team of researchers found that cigarettes made without tobacco or nicotine may be more carcinogenic because they actually induce more extensive DNA damage than tobacco products.

13 May 2010

CTI to conduct phase II study of pixantrone in patients with HER2-negative breast cancer

Cell Therapeutics, Inc. (CTI) today announced an agreement with the North Central Cancer Treatment Group (NCCTG) to conduct a phase II study of pixantrone in patients with HER2-negative metastatic breast cancer who have tumor progression after at least two, but not more than three, prior chemotherapy regimens.

13 May 2010

Tracking genes in infant's intestine helps compare early development of breast-fed and formula-fed babies

Is breast milk so different from infant formula? The ability to track which genes are operating in an infant's intestine has allowed University of Illinois scientists to compare the early development of breast-fed and formula-fed babies. They say the difference is very real.

13 May 2010

GTC Biotherapeutics reports lower total net loss of $7.7M for first-quarter 2010

GTC Biotherapeutics, Inc. today reported its financial results for the first fiscal quarter ended April 4, 2010. The total net loss for the first quarter was $7.7 million, or $0.26 per share, compared to $10.4 million, or $0.99 per share, for the first quarter of 2009.

12 May 2010

Bioniche third-quarter consolidated revenues increase 111% to $15.6 million

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its Fiscal 2010 third quarter, ended March 31, 2010.

12 May 2010

Patient enrollment completed in Phase 2 clinical trial of orBec for prevention of acute GVHD

Soligenix, Inc., a late-stage biopharmaceutical company, announced today that patient enrollment has been completed in a randomized, double-blind, placebo-controlled Phase 2 clinical trial of orBec for the prevention of acute Graft-versus-Host disease after allogeneic hematopoietic cell transplantation with myeloablative conditioning regimens.

12 May 2010

Sanford-Burnham Scientific Symposium provides wealth of information on microRNAs, RNAi

Investigators from around the country came to Sanford-Burnham Medical Research Institute (Sanford-Burnham) on Friday, May 7, to share their knowledge of the burgeoning young field of microRNAs. These small non-coding nucleic acids turn off proteins and have been implicated in viral infection, cancer, cardiovascular disease, HIV and numerous other conditions.

12 May 2010

Key mechanisms for delivery of LNP-encapsulated siRNAs to the liver

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the publication of pre-clinical research in the journal Molecular Therapy revealing key mechanisms related to the systemic delivery of RNAi therapeutics using lipid nanoparticles (LNPs).

12 May 2010

Mutations in STRAD-alpha gene can cause PMSE syndrome in Amish children: Penn researchers

So often the rare informs the common. Penn researchers investigating a regulatory protein involved in a rare genetic disease have shown that it may be related to epileptic and autistic symptoms in other more common neurological disorders.

12 May 2010

New approach to harness and modulate enzyme activity

An Arizona State University graduate student, Jinglin Fu, in collaboration with Biodesign Institute researchers Neal Woodbury and Stephen Albert Johnston, has pioneered a technique that improves on scientists' ability to harness and modulate enzyme activity.

12 May 2010

Drug-releasing stents do not result in fewer deaths or subsequent heart attacks after angioplasty

Drug-releasing stents are more effective than bare metal stents at keeping a blocked artery open after angioplasty, but the difference does not result in fewer deaths or subsequent heart attacks after the procedure, according to a review of recent studies.

12 May 2010

Benefits outweigh risks in myeloablative therapy for children with high-risk neuroblastoma

Neuroblastoma is among the most common of childhood cancers and fortunately, some children will get better spontaneously. Yet for children with high-risk disease the outlook is poor: more than half will relapse despite chemotherapy.

12 May 2010

BioGenes study documents insufficient sensitivity of ELISA-based generic HCP assay

BioGenes GmbH, a supplier of GMP-compliant immunoassays and antibodies, completed a study that documents the insufficient sensitivity of an ELISA-based generic host cell protein assay. The results confirm the observation of several contract manufacturers that generic HCP assays are only of limited use for detection of HCPs during manufacturing processes.

12 May 2010

Response Genetics, GSK sign non-exclusive license agreement for BRAF mutational analysis technology

Response Genetics, Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, today announced it has signed a non-exclusive license agreement with GlaxoSmithKline ("GSK"). Under the terms of the agreement, GSK gains certain rights to Response Genetics' proprietary PCR analysis technology and diagnostic expertise to assess BRAF gene mutations in human tumor samples. Payments will be made to Response Genetics upon achivement of agreed-to milestones.

12 May 2010

Optivia Biotechnology launches OptiDDI Suite for assessing transporter-related DDIs

Optivia Biotechnology Inc., a leading provider of in vitro transporter assay services, today announced the launch of the OptiDDITM Suite, a novel assay panel that assesses the most clinically significant transporter-related drug-drug interactions (DDIs), as identified by the International Transporter Consortium (ITC) in its report "Membrane Transporters in Drug Development" (Nature Reviews-Drug Discovery, March 2010).

12 May 2010

CEA-Leti launches TARGET-PDT project to increase effectiveness of PDT for treating cancer

CEA-Leti today announced the launch of the TARGET-PDT project designed to increase the effectiveness of photodynamic therapy for treating cancer by developing a novel nano carrier-based approach.

12 May 2010

Beike Biotechnology, Jiangsu government's CMC open world's largest stem cell management center

Beike Biotechnology Co. Ltd., one of the world's leading biotechnology companies focusing on adult stem cell therapies, and the Jiangsu government's China Medical City (CMC) opened China's state-of-the-art stem cell storage and processing facility today. The 20,000 square-meter Stem Cell Regenerative Medicine Industrial Project of National Bio-Industry Base (NBPD) houses China's first comprehensive regenerative medicine technology center and its largest international stem cell bank.

12 May 2010

ProBioGen signs contract with Virdante Biopharmaceuticals

ProBioGen AG, a technology and service provider for the development and production of biopharmaceutical drug substances today announced signing a contract with Virdante Biopharmaceuticals, Inc., a US-based biopharmaceutical development company.

12 May 2010

OXiGENE reports consolidated net loss of $11.0M for first-quarter 2010

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter ended March 31, 2010, and presented an update on recent clinical and corporate progress.

12 May 2010

T Cell News and Research

Latest T Cell News and Research

Additional benefits of LAIAs over long-acting human insulin not been proven

Tobacco-free cigarettes may be more carcinogenic than tobacco products: Study

CTI to conduct phase II study of pixantrone in patients with HER2-negative breast cancer

Tracking genes in infant's intestine helps compare early development of breast-fed and formula-fed babies

GTC Biotherapeutics reports lower total net loss of $7.7M for first-quarter 2010

Bioniche third-quarter consolidated revenues increase 111% to $15.6 million

Patient enrollment completed in Phase 2 clinical trial of orBec for prevention of acute GVHD

Sanford-Burnham Scientific Symposium provides wealth of information on microRNAs, RNAi

Key mechanisms for delivery of LNP-encapsulated siRNAs to the liver

Mutations in STRAD-alpha gene can cause PMSE syndrome in Amish children: Penn researchers

New approach to harness and modulate enzyme activity

Drug-releasing stents do not result in fewer deaths or subsequent heart attacks after angioplasty

Benefits outweigh risks in myeloablative therapy for children with high-risk neuroblastoma

BioGenes study documents insufficient sensitivity of ELISA-based generic HCP assay

Response Genetics, GSK sign non-exclusive license agreement for BRAF mutational analysis technology

Optivia Biotechnology launches OptiDDI Suite for assessing transporter-related DDIs

CEA-Leti launches TARGET-PDT project to increase effectiveness of PDT for treating cancer

Beike Biotechnology, Jiangsu government's CMC open world's largest stem cell management center

ProBioGen signs contract with Virdante Biopharmaceuticals

OXiGENE reports consolidated net loss of $11.0M for first-quarter 2010

Immunology eBook

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

Newsletters you may be interested in